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Abstract
Purpose Cancer stem cells (CSCs) are held accountable for the progress of head and neck squamous cell carcinoma
(HNSCC). In the presented study, the authors evaluated the prognostic value of CSC markers in two particular HNSCC
cohorts.
Methods This two cohort study consisted of 85 patients with advanced stage HNSCC, treated with primary ra-
dio(chemo)therapy (pRCT), and 95 patients with HNSCC, treated with surgery and partially adjuvant radio(chemo)therapy.
Overall survival (OS), disease-free survival (DFS), and disease-specific survival (DSS) were assessed. Samples were as-
sessed for the expression of different molecular stem cell markers (ALDH1, BCL11B, BMI-1, and CD44).
Results In the pRCT cohort, none of the baseline patient and tumor features exhibited a statistically significant relation
with survival in either the cohort or the human papillomavirus (HPV)-stratified subcohorts. High expression of BMI-1
significantly decreased OS and DFS, while high expression of CD44 decreased all modes of survival. Multivariate analysis
showed significant prognostic influence for all tested CSC markers, with high BMI-1 and CD44 decreasing survival (BMI-1:
OS, DFS, DSS; CD44: OS, DFS) and high ALDH1 and BCL11B showing a beneficial effect on survival (ALDH1: OS,
DFS; BCL11B: OS, DSS). In the surgical cohort, classical prognosticators such as HPV status, R1 resection, and nodal
status in HPV-negative HNSCC played a significant role, but the tested CSC markers showed no significant effect on
prognosis.
Conclusion Although validation in independent cohorts is still needed, testing for CSC markers in patients with advanced
or late stage HNSCC might be beneficial, especially if many comorbidities exist or disease is irresectable. The findings
might guide the development and earlier use of targeted therapies in the future.
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Introduction
Head and neck squamous cell cancer (HNSCC) is one of the
most prevalent cancers worldwide [1]. Risk factors include
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Table 1 General patient characteristics, risk factors, and disease stage of the primary radio(chemo)therapy (pRCT) cohort. All continuous data
variables are displayed as mean± standard deviation
Characteristics
pR(C)T cohort
Cohort (n= 85) HPV-neg. subcohort (n= 53) HPV-pos. subcohort (n= 31)
Gender Male 82.4% 81.1% 83.9%
Female 17.6% 18.9% 16.1%
Age at diagnosis (years) 58.3± 11.2 55.6± 10.7 62.4± 10.7
Relapse at diagnosis Positive 14.1% 9.4% 22.6%
Substance abuse Negative 14.1% 11.3% 16.1%
Nicotine (>10py) 21.2% 18.9% 25.8%




Insufficient data 3.5% 3.8% 3.2%
HPV status Positive 36.5% 0% 100%
Negative 62.4% 100% 0%
Not determinable 1.2% 0% 0%
Localization Oropharyngeal 35.3% 41.5% 25.8%
Oral cavity 32.9% 32.1% 35.5%
Hypopharyngeal 11.8% 9.4% 12.9%
Laryngeal 7.1% 9.4% 3.2%
Multi-site 12.9%a 7.5% 22.6%
Staging cT 1 4.7% 5.7% 3.2%
2 5.9% 1.9% 12.9%
3 11.8% 11.3% 12.9%
4 77.6% 81.1% 71.0%
cN positive 84.7% 88.7% 77.4%
cN 1 9.4% 11.3% 6.5%
2 68.2% 71.7% 64.5%
2b 12.9% 20.8% 16.1%
2c 24.7% 39.6% 32.3%
3 7.1% 5.7% 6.5%
cM1 8.2%b 5.7% 9.7%
Stage (UICC, 7th
edition)
II 3.5% 0% 9.7%
III 5.9% 5.7% 6.5%
IV 90.6% 94.3% 83.9%
Simultaneous
malignancy
Positive 1.2%c 1.9% 0%
Questionable 1.2% 1.9% 0%
Histology G1 3.5% 1.9% 6.5%
2 76.5% 79.2% 71.0%
3 20.0% 18.9% 22.6%
[2]. Of the mentioned risk factors, HPV exposure seems to
cause an increasing fraction of HNSCC incidence world-
wide, including Germany [3, 4].
Clinical outcome is dependent on tumor size, locore-
gional spread, resection margins, extracapsular extension,
lymphovascular invasion, and distant metastasis [5, 6].
Alongside TNM classification, HPV status can serve as
a marker to predict survival probabilities, which eventually
led to the development of a new TNM classification system
for p16-positive oropharyngeal carcinomas [6–8].
Despite improvements in diagnosis and treatment of HN-
SCC over the past decades, long-term survival has improved
only marginally [5, 9, 10]. To improve survival in HNSCC
patients, investigations into the underlying molecular and
phenotypic changes associated with tumorigenesis, disease
progression, and metastasis are necessary.
More recent studies have shown that survival of can-
cer stem cells (CSCs; also known as tumor-initiating cells)
may contribute to tumor progression, metastasis, and recur-






Cohort (n= 85) HPV-neg. subcohort (n= 53) HPV-pos. subcohort (n= 31)
Treatment Radiotherapy 100% 100% 100%
3D LatOP 52.9% 62.3% 38.7%
iMRT 20.0% 17.0% 25.8%
RA 3.5% 1.9% 6.5%
Kreuzfeuer 23.5% 18.9% 29.0%
Calculated dose 66Gy 9.4% 5.7% 12.9%
70Gy 90.6% 94.3% 87.1%
Paused 18.8% 9.4% 35.5%
Insufficient data 1.2% – 3.2%
Therapy abortion 9.4%d 1.9% 22.6%
Combined chemotherapy 80.0% 81.1% 83.9%
Platin + 35.3% 24.5% 51.6%
Platin – 44.7% 52.8% 32.3%
Paused 18.8% 13.2% 29.0%
Surgical debulking 1.2% 0% 3.2%
Status after pR(C)T Complete remission 54.1% 56.6% 51.6%
Partial remission 23.5% 26.4% 19.4%
Stable disease 7.1% 3.8% 12.9%
Progressive disease 7.1% 7.5% 3.2%
Insufficient data 8.2% 5.7% 12.9%
Relapse after pR(C)T Relapse in total 35.3% 39.6% 25.8%
Locoregional relapse 34.1% 39.6% 22.6%
Follow-up time
(months)
Median 15.3 14.3 17.8
Minimum 1.8d 1.8 2.6
Maximum 155.7 155.7 128.2
pR(C)T primary radio- or radiochemotherapy, UICC Union for International Cancer Control, 3D LatOP three-dimensional conformal radiation
therapy, iMRT intensity-modulated radiotherapy, RA radiofrequency ablation
aOro- and hypopharyngeal (n= 7); hypopharyngeal and laryngeal (n= 2); epi-, oro- and hypopharyngeal (n= 1), epi- and oropharyngeal (n= 1);
thereof HPV neg.: oro- and hypopharyngeal (n= 2); hypopharyngeal and laryngeal (n= 1); epi- and oropharyngeal (n= 1)
bPulmonal (n= 5), pleural (n= 1), intraorbital (n= 1), osseous (n= 1), cutaneous (n= 1); thereof HPV neg.: pulmonal (n= 2), pleural (n= 1)
cEsophageal squamous cell carcinoma (n= 1; HPV neg.)
dPatient died during therapy
to conventional therapy resistance and are responsible for
tumor progression and recurrence [13].
BMI-1, ALDH1, and CD44 are amongst the most com-
mon and most studied CSC markers in HNSCC [14].
BMI-1 (B-lymphoma Moloney murine leukemia virus in-
sertion region-1) acts in the self-renewal ability of stem
cells. High expression of BMI-1 in cancer was related to
epithelial–mesenchymal transition (EMT) and poor prog-
nosis [14, 15]. ALDH1 (aldehyde dehydrogenase 1) is
important for the maintenance and differentiation of stem
cells [16]. High ALDH1 expression was associated with ad-
vanced tumor stage, tumor size, and lymph node metastasis
[17]. CD44 is a surface glycoprotein and a common CSC
marker in several human tumor entities [18]. In oral can-
cer, high expression CD44 was linked to adverse outcome
[19]. In strong co-expression to BMI-1, BCL11B (B-cell
lymphoma/leukemia 11B) was identified as an additional
CSC marker in HNSCC that is otherwise observed in both
embryogenesis and tumor suppression [14, 20].
While there is already some data on the correlation with
disease characteristics such as tumor size, lymph node
metastasis, and grading, the correlation of CSC marker
expression and prognosis of survival is not well studied. In
this study, the authors therefore tested the prognostic value




In a single-center retrospective two cohort study, 184 pa-
tients were included. One cohort (primary radio[chemo]-
therapy cohort, pRCT cohort) included 89 patients. Con-
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Cohort (n= 95) HPV-neg. subcohort (n= 67) HPV-pos. subcohort (n= 28)
Gender Male 77.9% 76.1% 82.1%
Female 22.1% 23.9% 17.9%
Age at diagnosis (years) 59.5± 10.4 59.8± 11.2 58.6± 8.6
Relapse at diagnosis Positive 0% 0% 0%
Substance abuse Negative 37.9% 35.8% 42.9%
Nicotine (>10py) 28.4% 25.4% 35.7%
Alcohol 3.2% 4.5% 0%
Combined (nicotine+ alcohol) 30.5% 34.3% 21.4%
Insufficient data 0% 0% 0%
HPV status Positive 70.5% 0% 100%
Negative 29.5% 100% 0%
Not determinable 0% 0% 0%
Localization Oropharyngeal 69.5% 61.2% 89.3%
Oral cavity 22.1% 28.4% 7.1%
Hypopharyngeal 5.3% 7.5% 0%
Laryngeal 3.2% 3.0% 3.6%
Multi-site 0% 0% 0%
Staging pT 1 5.3% 4.5% 7.1%
2 23.2% 22.4% 25.0%
3 41.1% 37.3% 50.0%
4 30.5% 35.8% 17.9%
pN positive 72.6% 67.2% 85.7%
c/pN 0 27.4% 32.8% 14.3%
1 23.2% 23.9% 21.4%
2 47.4% 43.3% 57.1%
2b 34.7% 32.8% 39.3%
2c 8.4% 7.5% 10.7%
3 2.1% 0% 7.1%
ECE positive 17.9% 14.9% 35.7%
cM1 0% 0% 0%
R0 95.8% 94.0% 100%
1 4.2% 6.0% 0%
2 0% 0% 0%
Stage (UICC, 7th
edition)
I 1.1% 1.5% 0%
II 6.3% 9.0% 0%
III 29.5% 29.9% 28.6%
IV 63.2% 59.7% 71.4%
tinuous cases were included that were (1) diagnosed with
histopathologically confirmed advanced stage head and
neck squamous cell carcinoma between November 1998
and May 2012, and (2) treated with primary radiotherapy
or pRCT. All diagnostic and treatment procedures (3) had
to be performed in the same tertiary referral center. Patients
that (1) received pRCT in palliative intent with reduced
planned radiation dose and with (2) missing clinical data
or (3) retracted informed consent were excluded. Further
important reasons for exclusion included (4) insufficient
amounts of tumor tissue, (5) damaged specimen or failure
of immunohistochemistry control stainings.
The other cohort (surgical cohort) included 95 patients
that were (1) diagnosed with head and neck squamous
cell carcinoma between August 2001 and June 2015 and
(2) treated with surgical resection. Of these patients, 72
also underwent adjuvant radiotherapy or radiochemother-
apy. All diagnostic and treatment procedures (3) had to be
performed in the same tertiary referral center. Many pa-






Cohort (n= 95) HPV-neg. subcohort (n= 67) HPV-pos. subcohort (n= 28)
Simultaneous
malignancy
Positive 0% 0% 0%
Questionable 0% 0% 0%
Histology G1 1.1% 0% 3.6%
2 81.1% 88.1% 64.3%
3 17.9% 11.9% 32.1%
Indication for
adjuvant therapy
adjR(C)T indicated 88.4% 86.6% 92.9%
adjR(C)T not indicated 7.4% 9.0% 3.6%
Facultative 4.2% 4.5% 3.6%
adjR(C)T refused 16.8% 17.9% 14.3%
Relapse leading to adjR(C)T 3.2% 4.5% 0%
Treatment Radiotherapy 75.8% 73.1% 82.1%
Calculated dose 60Gy 5.3% 6.0% 3.6%
62.4Gy 34.7% 32.8% 39.3%
64Gy 35.8% 34.3% 39.3%
Paused 37.9% 34.3% 46.4%
Therapy abortion 2.1%a 3.0% 0%
Combined chemotherapy 60.0% 56.7% 67.9%
Paused 18.9% 7.5% 17.9%
Relapse after pR(C)T Relapse in total 33.7% 44.8% 7.1%
Locoregional relapse 26.3% 34.3% 7.1%
Follow-up time
(months)
Median 36.6 39.6 31.2
Minimum 4.7 4.8 4.7
Maximum 162.7 131.0 162.7
adjR(C)T adjuvant radio- or radiochemotherapy, UICC Union for International Cancer Control
aAbortion at 54Gy of calculated 64 and 58.24Gy of calculated 62.4Gy
consent. Also patients with (2) relapse at diagnosis, (3) dis-
tant spread at diagnosis, or (4) previous radiation therapy
for any cause before surgical treatment, (5) missing clinical
data, as well as (6) insufficient amounts of tumor tissue,
(7) damaged specimen or failure of immunohistochemistry
control stainings were excluded.
Clinical data, including risk factors such as smoking and
drinking habits, as well as data regarding disease stage and
therapy, were obtained from the medical documentation of
the patients. Histologic samples were collected and ana-
lyzed as described below.
In the pRCT cohort, out of 89 patients in total, HPV test-
ing showed valid results in 88 patients and molecular testing
of all of the tested markers could be obtained in the histo-
logic samples of 85 patients. Detailed patient characteristics
of these 85 patients are described in Table 1. In the surgi-
cal cohort, HPV and molecular testing could be obtained
in all 95 patients. Patient characteristics of the 95 patients
of the surgical cohort are described in Table 2. All data is
displayed for the entire sample set regardless of the HPV
status and separately for the HPV-distinct subcohorts.
All clinical samples were obtained with written informed
consent during routine surgery or biopsy based on the ap-
proval by the ethics committee of the local medical fac-
ulty and in compliance with the World Medical Association
Declaration of Helsinki.
Histological samples and immune staining
Specimens were formalin-fixed and paraffin-embedded.
Antigen expression was assessed in tissue microarrays
(TMAs) of biopsies from primary tumor specimens and
represented the average of two to four punches of 1.5mm
diameter, taken randomly from different regions within
each specimen. P16 status as a surrogate marker of HPV
infection will be referred to as HPV status in the following
(p16-specific antibodies: cs56330, Santa Cruz Biotechnol-
ogy) [21, 22]. Immunohistochemistry (IHC) was performed
using ALDH1-, BCL11B-, BMI-1-, and CD44-specific an-
tibodies (ALDH1: ab52492, abcam; BCL11B: HPA049117,
Sigma Aldrich; BMI-1: #6964, Cell Signaling Technology;
CD44: #3570, Cell Signaling Technology).
In order to quantify and compare expression levels, im-
munohistochemistry score (IHC scores) were applied to all
stainings. IHC scores represent the product of the percent-
ages of positive cells and the staining intensity scored from
negative (0), low (1), intermediate (2), to strong (3). They
have a range of 0–300 (Fig. 1a–d).
K
Strahlenther Onkol
Fig. 1 ALDH1, BCL11B,
BMI-1, and CD44 expression
in head and neck squamous
cell cancer (HNSCC) and dis-
tribution in the two study co-
horts. Shown are examples
of ALDH1 (a), BCL11B (b),
BMI-1 (c), and CD44 (d) ex-
pression ranging from none (0),
weak (1), and intermediate (2)
to strong (3) in HNSCC (200×).
ALDH1, BCL11B, BMI-1, and
CD44 staining is red-brown,
while nuclei and cytoplasm are
counter-stained with hemalaun
(blue). e Immunohistochemistry
(IHC) scores combine propor-
tions and intensities of staining
as described in “Material and
methods” for the four reported
stem cell markers ALDH1 (cy-
toplasmic expression), BCL11B
(nuclear), BMI-1 (nuclear), and
CD44 (cytoplasmic). Per defi-
nition, IHC scores could reach
values between 0 and 300. The
plots reflect the frequency distri-






Clinical endpoints, survival analysis, and statistical
analysis
Overall survival (OS), disease-free survival (DFS), and dis-
ease-specific survival (DSS) were chosen as clinical end-
points (in months). OS was calculated from the date of
diagnosis to the point of death by any cause, DFS to the
first observation of any recurrence or death, and DSS to the
date of HNSCC-related death. In the absence of an event,
patients were censored at the date of the last follow-up visit.
Survival data were analyzed by log rank test and visual-
ized as Kaplan-Meier plots. To define dichotomous cut-off
values for continuous IHC variables, an online tool (http://
molpath.charite.de/cutoff/) was applied [23]. Univariate and
multivariate analyses were conducted using Cox regression.
A p-value< 0.05 was considered statistically significant. All
further statistical procedures were conducted using SPSS,
version 12.0 (IBM).
Results
All 85 patients in the pRCT cohort were treated with pri-
mary radiotherapy or pRCT after diagnosis of advanced
stage HNSCC. The 95 patients in the surgical cohort re-
ceived surgical treatment with or without adjuvant radio-
therapy. Detailed patient characteristics, risk factors, dis-
ease staging, treatment, and post-treatment follow-up in-
cluding follow-up time of both cohorts are shown in Ta-
bles 1 and 2. Representative stainings and patterns of stem
cell marker distributions are displayed in Fig. 1. The most
abundant expression was detected for CD44, whereas it was
K
Strahlenther Onkol
Table 3 Pairwise correlation coefficients as assessed by Kendall’s τ with respective p-values. p Values< 0.05 are highlighted in bold-italic.
Italic= primary radio(chemo)therapy cohort, bold= surgical cohort
ALDH1 BCL11B BMI-1 CD44
ALDH1 τ – 0.16 0.22 0.11
p – 0.119 0.015 0.266
BCL11B τ 0.13 – 0.46 0.11
p 0.162 – <0.001 0.267
BMI-1 τ 0.06 0.34 – 0.18
p 0.534 <0.001 – 0.045
CD44 τ 0.18 0.17 0.24 –
p 0.052 0.063 0.008 –
Fig. 2 Association of human
papillomavirus (HPV) status
with clinical outcome in the
surgical cohort and the primary
radio(chemo)therapy (pRCT)
cohort and association of single
ALDH1, BCL11B, BMI-1, and
CD44 IHC scores with clinical
outcome in the pRCT cohort.
a Kaplan-Meier curves for the
endpoints overall survival (OS),
disease-free survival (DFS), and
disease-specific survival (DSS)
in head and neck squamous cell
cancer (HNSCC) patients strat-
ified according to HPV status
(HPV-positive versus HPV-neg-
ative). p-Values (log-rank test)
are indicated. b Kaplan-Meier
curves for OS, DFS, and DSS in
HNSCC patients stratified into
groups with low and high ex-
pression of ALDH1, BCL11B,
BMI-1, and CD44. p-Values
(log-rank test) and the applied
optimized threshold for the clas-
sification of patient subgroups






Table 4 Univariate Cox regression analysis for the four investigated immunohistochemistry parameters in the primary radio(chemo)therapy
cohort. P-values< 0.05 are highlighted in bold. CO: cut-off values; HR (95% CI): hazard ratio with 95% confidence interval
OS DFS DSS



















































































OS overall survival, DFS disease-free survival, DSS disease-specific survival
absent for ALDH1 in most tumors. Deviations between
the two study cohorts were most pronounced for BMI-1
(p< 0.001, Mann-Whitney U test), less distinct for BCL11B
(p= 0.016), and absent for ALDH1 (p= 0.922) and CD44
(p= 0.892). IHC staining was positively correlated in par-
ticular between BC11B and BMI-1 in both study cohorts;
however, the correlation coefficients did not exceed 0.5 in
either case. Weaker positive correlations were observed be-
tween ALDH1 and BMI-1 (pRCT cohort only) and between
BMI-1 and CD44 (both cohorts) (Table 3).
Baseline features andmolecularmarkers in the pRCT
cohort
First, univariate Cox regression analysis was performed for
baseline patient and tumor features with respect to OS, DFS,
and DSS. Age was used as a continuous variable, while the
other parameters are dichotomous (Supplemental Table 1).
None of the baseline features exhibited a statistically sig-
nificant relation with either OS, DFS, or DSS in the entire
sample set (see Supplemental Table 1) or in the subsets
stratified by HPV status (all p> 0.05). In particular, HPV
status had no significant effect on survival (OS: p 0.38,
DFS: p 0.39, DSS: p 0.27; log rank; Fig. 2a).
Thereafter, univariate Cox regression analysis was per-
formed for the four investigated IHC parameters stained.
For each staining parameter cut-off (CO), values were de-
termined each for OS, DFS, and DSS. Analyses were each
done for the entire pRCT cohort and, using the same COs,
for the HPV-distinct subcohorts (Table 4). In the single
marker analyses of the pRCT cohort, high expression of
BMI-1 was associated with a significantly decreased OS
and DFS and a tendency to decreased DSS (OS: p 0.031,
DFS: p 0.048, DSS: p 0.077; log rank). High expression
of CD44 was associated with all types of survival (OS:
p 0.008, DFS: p 0.007, DSS: p 0.036; log rank). High ex-
pression of ALDH1 showed a tendency to increased OS and
DFS (OS: p 0.091, DFS: p 0.084; log rank). For the sin-
gle marker analysis of BCL11B, no significant differences
were observed (Table 4; Fig. 2b).
In the HPV-positive subcohort, no significant differences
were observed between high and low marker expression.
High expression of CD44 showed a tendency to decreased
OS and DFS (OS: p 0.055, DFS: p 0.051; log rank; Table 4;
Fig. 3a). In the HPV-negative subcohort, no significant dif-
ferences were observed between high and low marker ex-
pression. High expression of BMI-1 showed a tendency to
decreased OS and DFS (OS: p 0.081, DFS: p 0.090; log
rank; Table 4; Fig. 3b).
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Fig. 3 Association of single
ALDH1, BCL11B, BMI-1, and
CD44 immunohistochemistry
scores with clinical outcome




for overall survival (OS), dis-
ease-free survival (DFS), and
disease-specific survival (DSS)
in head and neck squamous
cell carcinoma patients strati-
fied into groups with low and
high expression of ALDH1,
BCL11B, BMI-1, and CD44.
p-Values (log-rank test) and
the applied optimized threshold
for the classification of patient
subgroups are indicated for the
HPV-positive subcohort (a) and
the HPV-negative subcohort (b)
a
b
To assess covariate effects in the pRCT cohort, a multi-
variable Cox regression model comprising patient-, tumor-,
and therapy-related features as well as the four IHC pa-
rameters (each stratified by the optimized threshold with
regard to either OS, DFS, and DSS) was conducted. Of
the patient-, tumor-, and therapy-related features, only
concomitant chemotherapy was associated with favorable
outcome (p 0.035, Table 5). In the HPV-stratified subco-
horts, no significant associations were observed. For the
four tested CSC markers, multivariable analysis showed
significant prognostic influence of BMI-1, with CD44
decreasing survival (BMI-1: OS, DFS, and DSS; CD44:
OS, DFS and DSS), and ALDH1 and BCL11B support-
ing survival (ALDH1: OS, and DFS; BCL11B: OS, and
DSS) (Table 5). In a multivariable analysis of the four
tested CSC markers only, similar results were found for
K
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Table 5 Multivariable Cox regression model comprising patient-, tumor-, and therapy-related features as well as the four immunohistochemistry
parameters in the primary radio(chemo)therapy (pRCT) cohort. p-Values< 0.05 are highlighted in bold. “Model” refers to the overall score
encompassing all 13 variables. “Former HNSCC”: 14 patients were treated within the presented study for relapse of head and neck squamous cell
cancer (HNSCC). “RT complete”: radiotherapy was completed in 82 patients and prematurely stopped in seven. “Chemotherapy”: 72 patients
received chemotherapy concomitant to radiation
OS DFS DSS












































































ALDH1 ≥7.5 vs <7.5 0.39
(0.20–0.79)







BCL11B ≥5.0 vs <5.0 0.31
(0.15–0.64)
0.002 ≥55.0 vs 7.5 0.63
(0.32–1.28)



























Model – χ2= 35.89 0.001 – χ2= 29.47 0.006 – χ2= 22.17 0.053
OS overall survival, DFS disease-free survival, DSS disease-specific survival
the whole pRCT cohort (Supplemental Table 2). For the
HPV-negative subcohort, high expression of BMI-1 was
associated with significantly decreased OS. In the HPV-
positive subcohort, OS was reduced with high expression of
BMI-1; DFS was decreased with high expression of CD44
and low expression of ALDH1 (Supplemental Table 2).
Baseline features and molecular markers in the
surgical cohort
Accordingly, univariate Cox regression analysis was per-
formed for baseline patient and tumor features with respect
to OS, DFS, and DSS, in the surgical cohort. Age was used
as a continuous variable, while the other parameters are
dichotomous (Table 6).
In the surgical cohort, the authors found a significant
reduction of survival in patients with R1-resection (OS:
p 0.0002, DFS: p 0.006, DSS: p 0.004; log rank). Also,
DFS was significantly decreased in patients with no HPV
association; OS only tended to decrease (DFS: p 0.008, OS:
p 0.066; log rank; Table 6; Fig. 2a). In the HPV-negative
subcohort, node metastasis significantly decreased both OS
and DSS (OS: p 0.042, DSS: p 0.040; log rank; Table 6).
Thereafter, univariate Cox regression analysis was per-
formed for the four investigated IHC parameters stained,
accordingly to the pRCT cohort. For each staining param-
eter, CO values were determined each for OS, DFS, and
DSS, using the same COs for all (sub)cohorts. None of
the four investigated IHC parameters exhibited a statisti-
cally significant relation with either OS, DFS, or DSS in
the entire sample set (Supplemental Table 3) or in the sub-
sets stratified by HPV status (all p> 0.05). Therefore, no
multivariable Cox regression model was conducted in the
surgical cohort.
Discussion
In HNSCC, classical prognosticators include age, comor-
bidities, performance status, frailty, and advanced tumor
K
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Table 6 Univariate Cox regression analysis for baseline patient and tumor features in the surgical cohort. p-Values< 0.05 are highlighted in bold.
HR (95% CI): hazard ratio with 95% confidence interval
OS DFS DSS
HR (95% CI) P HR (95% CI) P HR (95% CI) P
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stage [24], as well as nodal status [25], especially extracap-
sular extension [26], and close or involved margin resec-
tion [26, 27]. Especially in advanced stage cancer, data and
knowledge on prognosis are very limited [28]. For some
time, HPV association has been a known factor in HNSCC
prognosis [29, 30]. Therefore, the International Collabora-
tion on Oropharyngeal cancer Network for Staging (ICON-
S) proposed an alternative staging system that eventually
led to the independent HPV-positive oropharyngeal cancer
classification in the 8th edition of the Union for Interna-
tional Cancer Control/American Joint Committee on Can-
cer TNM classification [8]. The data presented here support
this hypothesis, but only in the surgical cohort.
While in the surgical cohort R status, HPV status, and
nodal status were prognostic survival markers (worse prog-
nosis after R1 resection, in HPV–, and HPV– N+ disease),
these factors, and especially HPV status, were not relevant
factors for prognosis in the pRCT cohort. In early stage can-
cer, prognosis may be driven by cancer biology such as tu-
mor stage, histological grade, and mutation status, whereas
prognostic variables in patients with advanced cancer tend
to consist of patient-related factors such as performance sta-
tus and cancer anorexia/cachexia [31]. In the current study,
the prognostic indifference of HPV status in the pRCT co-
hort might be explained by a selection bias of relatively
sick patients with a high number of relevant comorbidities
and low performance status. Unfortunately, robust data on




Interestingly, the authors did not see any significant ef-
fect of the tested CSC markers in the surgical cohort. A pos-
sible explanation is too short a follow-up time. One other
reason might be a rather small sample size being responsible
for no significance in the univariate analyses of the tested
molecular markers, especially in the surgical cohort. In gen-
eral, there might be a relevant selection bias in the surgi-
cal cohort, since many primarily identified patients needed
to be excluded as described in “Material and methods”.
Regardless, the molecular CSC markers had a significant
influence in the pRCT cohort with a comparable sample
size and an only slightly longer follow-up time. Although
TNM staging seems similar in both cohorts, the two cohorts
cannot be considered fully comparable since co-morbidi-
ties and especially non-resectability might be strong con-
founders for survival. In this retrospective investigation, it
was inconclusive in some cases what exactly triggered the
therapy decision, especially in the pRCT cohort. Presum-
ably, overall prognosis in the pRCT cohort is a priori worse
than in the surgical cohort. Therefore, results of the cohorts
must be seen independently from each other. In general, the
retrospective manner of the investigation and missing val-
idation in independent cohorts are limitations of the study
design.
Recently, the number of molecular markers linked to
survival increased considerably [26]. The identification of
new markers in cancer is crucial to develop better forecasts
on prognosis and to find new therapy options [5, 7, 19, 32].
In this field of research, CSC markers are very prominent,
although some are linked to a better and some to a worse
prognosis, whereas the literature is controversial for some
markers [12, 13, 33, 34].
Of the CSC markers, CD44 is of the highest clinical rel-
evance. It was demonstrated that expression of CD44 iso-
forms in HNSCC is differently associated with advanced
T stage, regional and distant metastasis, and radiation fail-
ure, which suggests an involvement of CD44 in HNSCC
tumor cell proliferation and migration [35]. In the present
surgical cohort, different CSC marker expression did not al-
ter survival prognosis, but in the pRCT cohort, high CD44
expression was associated with poorer survival (OS, DFS,
and DSS). These results support the findings that identified
high levels of CD44 mRNA, CD44 protein, and SCL3A2
mRNA expression as prognosticators for local recurrence
in HNSCC after adjuvant RCT [36]. These findings have
been validated for an independent patient cohort with lo-
cally advanced HNSCC after adjuvant RCT and for a co-
hort of HNSCC patients receiving pRCT [36, 37]. CD44
levels have also been correlated with clinical response to
radiotherapy and may predict local recurrence in patients
with early-stage laryngeal cancers and local recurrence and
progression-free survival in oropharyngeal SCC [38, 39].
While CD44 plays an emerging role in HNSCC prognosti-
cation, the development of an anti-CD44 immunoconjugate
bivatuzumab mertansine for therapeutic use in patients with
advanced HNSCC was terminated after the immunoconju-
gate resulted in skin toxicity [40]. In oropharyngeal SCC
patients, low CD44 expression levels in combination with
HPV positivity were found to be positively associated with
3-year DFS and OS after undergoing different therapy reg-
imens [41].
The polycomb complex protein BMI-1 is frequently
overexpressed in HNSCC and increased BMI-1 expression
was associated with cervical node metastasis, Ki-67 abun-
dance, and reduced OS and also served as an independent
prognostic factor for patient outcomes in oral cavity SCC
[42]. While some studies could not predict survival from
BMI-1 expression [43, 44], other studies demonstrated
decreased radiosensitivity and increased probability for
distant metastases in an experimental setting [45]. The data
presented here demonstrate different perspectives on BMI-1
in HNSCC: While it was not associated with survival in
the surgical cohort, BMI-1 was a strong and negative prog-
nosticator in the pRCT cohort. Frequently, BMI-1 has been
linked to other CSC markers such as ALDH1 and BCL11B
[20, 45, 46].
ALDH family proteins belong to the most studied CSC
markers in HNSCC. These proteins are increased under cis-
platin treatment and radiotherapy and mediate CSC survival
in HNSCC [14]. Targeting of ALDH+ cells decreased tumor
burden and sensitized HNSCC cells for cisplatin treatment
[47]. ALDH1 was well correlated with tumor size, lymph
node metastasis, and histopathological grading in HNSCC,
being predominantly found in more aggressive tumors and
higher tumor stage [14, 17, 48]. ALDH1 and other pro-
teins from the ALDH family belong to the most preva-
lent markers to identify CSC in HNSCC [34]. ALDH1 ex-
pression was linked to treatment resistance, CSC-like prop-
erties, higher circulating myeloid-derived suppressor cells,
and poor prognosis as well as angiolympathic invasion in
oral cavity SCC [49, 50]. Although in the literature high
ALDH1 expression was mostly correlated to worse prog-
nosis [51, 52], the authors could not show an effect on
survival in their surgical cohort. In the pRCT cohort, high
ALDH1 even correlated with better outcome in the multi-
variate analysis and tended to do so in univariate analysis.
Strongly linked to BMI-1, BCL11B was suggested as
a marker to identify CSCs in HNSCC [20]. This link is sup-
ported by the authors’ findings in the correlation analysis
of the tested CSC markers. Predominantly studied in T-cell
malignancies, high BCL11B expression indicated a favor-
able outcome in patients [20, 53]. Similarly, the authors
could show in their data that high expression of BCL11B
was protective in the multivariate analysis of the CSC mark-
ers in the pRCT cohort.
K
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Although all of the markers are discussed as identify-
ing CSCs, it is possible that the authors’ data show a dif-
ferential perspective on the four tested markers regarding
prognosis in the pRCT cohort. One explanation might be
a heterogeneity in CSCs, with different types or states of
CSCs promoting disease progression and others slowing it
down. The present data suggest that CD44 and BMI-1 are
linked to poorer prognosis, whereas ALDH1 and BCL11B
are linked to tendentially better prognosis.
All studies on clinical correlations of the expression of
CSC markers, including the present study, have only lim-
ited scope to consider intratumoral heterogeneity as well as
tumor/metastasis heterogeneity. Experimental data suggest
that expression profiles of CSC and EMT markers may vary
within tumors and during metastasizing [54]. Innovative ap-
proaches are warranted in order to take into account these
aspects in the future. In the age of precision medicine and
increasing numbers of approaches in HNSCC treatment,
CSC markers, such as ALDH, CD44, BMI-1, and Sox2,
as well as c-Met and EGFR, yield opportunities to further
stratify prognosticators and gain therapy targets [34, 55].
The authors’ data emphasize the role of interdisciplinary
clinical conferences especially in advanced stage patients
with comorbidities to thoroughly identify separate prog-
nostic features and search for alternate targeted therapy ap-
proaches.
Conclusion
This two cohort study is the first to show remarkable differ-
ences for prognosticators in HNSCC between patients that
received either surgical treatment, with or without adjuvant
therapy, or were treated with pRCT .
In the pRCT cohort of advanced stage HNSCC patients,
CSC markers had a differential effect on survival, while
HPV status had no significant influence. Of the CSC mark-
ers, BMI-1 and CD44 indicated a significantly worse prog-
nosis on survival. However, ALDH1 and BCL11B appear
to have protective properties in HNSCC survival.
In a cohort with mostly advanced stage HNSCC patients
that were suitable for and treated with surgery and with or
without adjuvant radio(chemo)therapy, classical prognostic
factors such as HPV status, R1 resection, and nodal sta-
tus in HPV-negative HNSCC played a significant role in
survival prognosis, but the tested CSC markers showed no
significant effect on survival prognosis.
In conclusion, testing for CSC markers might be benefi-
cial in patients with advanced or late stage HNSCC, espe-
cially if many comorbidities exist or disease is inoperable.
In these cases, and if the findings can be validated in inde-
pendent cohorts, early molecular testing in interdisciplinary
clinical conferences might be beneficial, e.g., for earlier ap-
plication of targeted therapies.
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